c-MET amplification by FISH : 1015608

Please provide most recent Pathology report.

MDFCPCMET or 1015608

MET; cMet; Mesencymal Epithelial Transition Factor; c MET; c-MET

Tissue.

Paraffin embedded formalin fixed tissue that has been fixed in 10% neutral buffered formalin for at least 6 hours and no longer than 48 hours. Two unstained slides, with tissue of 4 microns in thickness are needed for processing, accompanied by a circled H & E clearly indicating the area to be examined.

Paraffin embedded tissue block: Ambient or on ice pack in summer. Slides: Ambient.

Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

Monday - Friday

Up to 7 days

Laboratory test results should always be considered in the context of clinical observations. This test was developed and its performance characteristics determined by med fusion. It has not been cleared or approved by the U.S. Food and Drug Administration(FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendmentsof 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.

An interpretive report will be provided.

cMET is the receptor for hepatocyte growth factor. Survival outcome of NSCLC patients with a mean of ≥ 5 copies of MET/cell is shorter than survival of patients with less than 5 copies of MET/cell. Therefor cMET represents an emerging therapy target for monoclonal antibodies and tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC). In addition, cMET activation has been associated with resistance to EGFR inhibitors both preclinically and clinically. Collectively, these findings support the rationale for dual inhibition of MET and EGFR signaling.